QUOTED. Jan. 23, 2018. Scott Whitaker.
Executive SummaryCheck out what AdvaMed CEO Scott Whitaker had to say about Congress’ move to suspend the device tax after many fits and starts in 2017.
"Congress' action to once again suspend the medical device tax – just days before companies were set to start cutting checks to the IRS – means funds will not be diverted from investing in new jobs, new capital improvements, and new treatments and cures. We appreciate Congress' action." –Scott Whitaker, president and CEO, AdvaMed
> Find out more: US Senate Votes To End Shutdown, Clinches Two-Year Device-Tax Repeal
Click here for a free trial of Medtech Insight